Aaron Miller, MD
Ophthalmology · Shenandoah, TXNPI 1912936642
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,500 of the $4,100 with a category attached, or 61.0%. Leadiant Biosciences, Inc. accounts for 61.0% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $2,711 and has fallen 91.6% since, to $229 in 2025.
Across 57 payments — averaging $71.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Leadiant Biosciences, Inc.$3K
- Amgen$278
- AbbVie$215
- Pacira Pharmaceuticals Incorporated$187
- Carl Zeiss Meditec USA, Inc.$151
- Coopervision Inc.$91
- plus $678 from 17 others
What the payments were for
- Consulting fees$2,50061%
- Food & beverage$1,58039%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Leadiant Biosciences, Inc. | 1 | $2,500 |
| Amgen(2 entities) | 12 | $278 |
| AbbVie(2 entities) | 9 | $215 |
| Pacira Pharmaceuticals Incorporated | 2 | $187 |
| Carl Zeiss Meditec USA, Inc. | 2 | $151 |
| Coopervision Inc. | 1 | $91 |
| Sun Pharmaceutical Industries Inc. | 4 | $80 |
| Rxsight Inc | 1 | $60 |
| Sanofi | 4 | $60 |
| Biotissue Holdings Inc. | 2 | $50 |
| Carl Zeiss Meditec, Inc. | 1 | $48 |
| Alcon | 2 | $47 |
| Thea Pharma Inc. | 2 | $44 |
| Aerie Pharmaceuticals, Inc. | 2 | $41 |
| United Therapeutics Corporation | 2 | $39 |
| Eyevance Pharmaceuticals LLC | 2 | $39 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Dompe US, Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $26 |
| Glaukos Corporation | 1 | $22 |
| Celularity Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXPAREL$101
How this compares
$4,100 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 92 | $922 |
| Prednisolone Acetate | 16 | $534 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Shenandoah
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.